Anthrax vaccines

iNtRON Completes GLP-TOX Studies of BAL200

Retrieved on: 
Tuesday, June 7, 2022
Intron, Orphan drug, CFR, PEPS, Company, China Biologic Products, CTO, Licensure, IPO, Safety, R, Central nervous system, CEO, GLP, News, Protein engineering, ODD, Plasma protein binding, Investment, IND, FDA, NHP, Biotechnology, Risk, Infection, PEP, Cros, COVID-19, BLA, Diagnosis, Toxicology, Anthrax, Post-exposure prophylaxis, Drug development, CMC, Bacteria, BD, CRO, Person, Anthrax vaccines, Pharmaceutical industry

BOSTON and SEOUL, Korea, June 6, 2022 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON" or "Company") announced today that the company has successfully completed the GLP toxicology studies of BAL200.

Key Points: 
  • BOSTON and SEOUL, Korea, June 6, 2022 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON" or "Company") announced today that the company has successfully completed the GLP toxicology studies of BAL200.
  • The company has completed the general GLP toxicology and safety pharmacology studies with final test reports and has obtained data essential for a licensing deal discussion of BAL200.
  • BAL200 is a new biological drug candidatebeing internally developed by iNtRON based on its various biotechnologies including bacteriophage, endolysin, protein engineering, and immunology technology.
  • "Since relevant studies including GLP-TOX with CROs and related companies in overseas are getting back on track from the delay due to the COVID-19 shut- down, we were able to complete the related studies for BAL200 recently," said Kyung Won YOON, CEO of iNtRON.

Anthrax Vaccine Market Research Report 2021: Global Growth, Trends, COVID-19 Impact, and Forecasts to 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 11, 2021
Health, Pharmaceutical, Proton, Poultry, Hair, Diagnosis, CDC, Bayer, Cattle, Hospital, Risk, CAGR, Animal, Human, Livestock, Center, Anthrax, Anthrax vaccines, COVID-19, Vaccine, Horse, Goat, Sheep, Centers for Disease Control and Prevention, Soil, Mark (given name), Research, Prevalence, Vaccination, Government, AEI, Awareness, Infection, Dog, Meat, Disease, Antelope, Animal husbandry

The "Anthrax Vaccine Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anthrax Vaccine Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
  • The Anthrax Vaccine Market is expected to project growth with an estimated CAGR of 7.85% during the forecast period.
  • Thus, Covid-19 is expected to have a slight negative impact on the anthrax vaccine market.
  • The anthrax vaccine market is a consolidated market with a limited number of players both in the human and animal segments.

Altimmune Reports Data from its Phase 1b Clinical Trial of NasoShield™

Retrieved on: 
Thursday, April 1, 2021
Medical specialties, Medicine, Health, Vaccines, Anthrax, Biological warfare, Anthrax vaccines, Immunogenicity, Vaccine trial

GAITHERSBURG, Md., April 01, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported clinical data today on its NasoShield intranasal anthrax vaccine candidate.

Key Points: 
  • GAITHERSBURG, Md., April 01, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported clinical data today on its NasoShield intranasal anthrax vaccine candidate.
  • The Phase 1b trial evaluated the safety and immunogenicity of one and two-dose regimens of NasoShield in healthy volunteers.
  • The trial enrolled 42 healthy subjects who received intranasally administered NasoShield or saline placebo and were then monitored for 6 months post-dosing.
  • The clinical data from the Phase 1b trial showed that:
    Serum binding antibody responses to the protective antigen of Bacillus anthracis, the bacterium and causative agent of anthrax, were significantly greater than in the placebo arm.

ServiceNow, Supporting Vaccinations for More Than 20 Million People Globally, Enhances Vaccine Administration Management Solution to Help Organizations Rapidly Administer COVID Vaccines at Scale

Retrieved on: 
Wednesday, March 17, 2021
Software, General Health, Mobile, Wireless, Professional services, Internet, Data management, Technology, White House, Federal Government, Infectious diseases, State, Local, Human resources, Health, Public policy, Government, Vaccines, Medical specialties, Medicine, Life sciences, Vaccination, Vaccine, Virology, Deployment of COVID-19 vaccines, Anthrax vaccines

The Now Platform and Vaccine Administration Management solution are being deployed in just days by some providers, using ServiceNows workflow technology to rapidly improve vaccine distribution, administration, and monitoring.

Key Points: 
  • The Now Platform and Vaccine Administration Management solution are being deployed in just days by some providers, using ServiceNows workflow technology to rapidly improve vaccine distribution, administration, and monitoring.
  • Additionally, Childrens Minnesota, one of the largest pediatric health care systems in the U.S., recently went live with ServiceNow Vaccine Administration Management in just five days.
  • Right now, that means ensuring our vaccine management process is efficient and able to get our community vaccinated as quickly as possible.
  • The latest updates to the ServiceNow Vaccine Administration Management solution improve the vaccination scheduling process for vaccine recipients, administrators, and clinicians, providing increased visibility into inventory, to help convert all available vaccines into vaccinations.

Altimmune Completes Enrollment in Phase 1b Clinical Trial of NasoShield™, a Single Dose Intranasal Anthrax Vaccine Candidate

Retrieved on: 
Friday, August 7, 2020
Vaccines, Medicine, Medical specialties, Health, COVID-19 vaccine, Vaccine, Anthrax vaccines, Herpes simplex research, Novavax

GAITHERSBURG, Md., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has completed enrollment in its Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate.

Key Points: 
  • GAITHERSBURG, Md., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has completed enrollment in its Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate.
  • Earlier this quarter, the Company reported positive preclinical data on AdCOVID, a single dose intranasal COVID-19 vaccine candidate which is derived from the same replication-deficient adenovirus 5 vaccine platform technology as NasoShield.
  • The Company plans to initiate a Phase 1 clinical trial of AdCOVID during the fourth quarter of 2020.
  • Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease.

Altimmune Announces Dosing of First Patient in Phase 1b Clinical Trial of NasoShield™, a Single Dose Intranasal Anthrax Vaccine Candidate

Retrieved on: 
Tuesday, June 30, 2020
Medical specialties, Health, Medicine, Immunology, Vaccines, Virology, RTT, Glycoproteins, Anthrax vaccines, Immunogenicity, Vaccine, Biopharmaceutical

GAITHERSBURG, Md., June 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced dosing of the first patient in the Companys Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate.

Key Points: 
  • GAITHERSBURG, Md., June 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced dosing of the first patient in the Companys Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate.
  • The clinical trial is expected to enroll 42 healthy subjects who will receive intranasally administered NasoShield or placebo and be followed for 6 months.
  • The primary immunogenicity readouts are the serum titers of antibody to protective antigen and toxin-neutralizing antibody 28 and 56 days after dosing.
  • Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies and intranasal vaccines.

BlueWillow Receives FDA Clearance to Begin Phase 1 Study of its Intranasal Anthrax Vaccine

Retrieved on: 
Wednesday, October 23, 2019
Medicine, Medical specialties, Vaccines, Drugs, Anthrax, RTT, Biological warfare, Vaccination, Anthrax vaccines, Vaccine

Development of an intranasal anthrax vaccine is ongoing through BlueWillow's partnership with Porton Biopharma Limited (PBL) under contract #HHSN272201600045C from NIAID for the development of a next-generation NanoVax anthrax vaccine.

Key Points: 
  • Development of an intranasal anthrax vaccine is ongoing through BlueWillow's partnership with Porton Biopharma Limited (PBL) under contract #HHSN272201600045C from NIAID for the development of a next-generation NanoVax anthrax vaccine.
  • The vaccine combines BlueWillow's novel intranasal NanoVax system with recombinant protective antigen (rPA) for anthrax from PBL.
  • The currently licensed injectable vaccine requires three immunizations in addition to antimicrobial therapy as a medical countermeasure following potential anthrax exposure.
  • "The BlueWillow/PBL anthrax vaccine has the potential to provide significant advantages over the current injectable vaccine," said BlueWillow CEODave Peralta.